ArticleNature2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.
Abstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers.
0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
210 citing papers in PubMed.
- Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation.Nature chemical biology · 2026Article
- Selective and Potent First-in-Class CRBN-Dependent Molecular Glue Degraders of WW Domain-Binding Protein 4.Angewandte Chemie (International ed. in English) · 2026Article
- Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery.Medicinal research reviews · 2026Review
- Article
- Charged molecular glue discovery enabled by targeted degron display.Nature chemical biology · 2026Article
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- High-throughput ligand diversification to discover chemical inducers of proximity.Nature chemical biology · 2026Article
- Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026Review
- A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Proteome-wide identification of the druggable CRBN interactome.Nature biotechnology · 2026Article
- Proteomics-Driven Strategies for Proximity-Inducing Drug Discovery.Angewandte Chemie (International ed. in English) · 2026Review
- Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies.Nature reviews. Drug discovery · 2026Review
- A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition.Journal of the American Chemical Society · 2026Article
- Targeted protein degradation: bridging chemical biology and clinical translation.Acta pharmacologica Sinica · 2026Review
- Molecular glue degraders: Rational design, specificity engineering, and advanced delivery.Acta pharmaceutica Sinica. B · 2026Review
- Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CAND1 and CAND2 drive CUL4 substrate receptor exchange with largely comparable biochemical efficiency, unlike their relative effects on CUL1.Structure (London, England : 1993) · 2026Article
- Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders.Chemical reviews · 2026Review
- Localized heme sensing through a ternary molecular glue.bioRxiv : the preprint server for biology · 2026Article
- Halofuginone is a Molecular Glue Degrader of Integrin β4.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
150 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Mikołaj Słabicki *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Zuzanna Kozicka *Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Georg Petzold *Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Yen-Der LiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Manisha ManojkumarBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Richard D BunkerFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Katherine A DonovanDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8539-5106
Quinlan L SieversBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jonas KoeppelBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1306-3994
Dakota SuchytaFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Adam S SperlingBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Emma C FinkBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jessica A GasserBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Li R WangBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven M CorselloBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9929-3709
Rob S SellarBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Max JanBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Dennis GillinghamFaculty of Science, University of Basel, Basel, Switzerland.
Claudia SchollDivision of Applied Functional Genomics, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Stefan FröhlingDivision of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Todd R GolubBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0113-2403
Eric S FischerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7337-6306
Nicolas H ThomäFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland. nicolas.thoma@fmi.ch.ORCID http://orcid.org/0000-0003-2685-906X
Benjamin L EbertBroad Institute of MIT and Harvard, Cambridge, MA, USA. benjamin_ebert@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-0197-5451
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI Zuzana Tothova · 1996 to 2026
$52.5MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MTyrosine Kinases, Serine-Threonine Kinases,&Phosophatases in PathogenesisP01CA108631 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ESTEY, ELIHU · 2005 to 2009
$9.7MInstitutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MThe role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9MDegrading therapeutically important kinases using small moleculesR01CA218278 · NCI · STANFORD UNIVERSITY · PI Eric Sebastian Fischer, NATHANAEL Schiander GRAY · 2019 to 2026
$4.6MThe molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.R01CA214608 · NCI · DANA-FARBER CANCER INST · PI Eric Sebastian Fischer · 2017 to 2026
$4.0MTargeting casein kinase 1-alpha for cancer therapyK08CA230220 · NCI · STANFORD UNIVERSITY · PI CORSELLO, STEVEN MUNTEAN · 2018 to 2022
$1.0MCancer Research UK 29036Howard Hughes Medical InstituteNCATS NIH HHS KL2 TR002542NCI NIH HHS K08 CA230220NCI NIH HHS P01 CA066996NCI NIH HHS P01 CA108631NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA214608NCI NIH HHS R01 CA218278NCI NIH HHS R35 CA253125NHLBI NIH HHS R01 HL082945NIGMS NIH HHS T32 GM007753
Abstract
Molecular glue compounds induce protein-protein interactions that, in the context of a ubiquitin ligase, lead to protein degradation
Indexed as
Cell Line, TumorCyclin-Dependent KinasesCyclinsDNA-Binding ProteinsHumansModels, MolecularProteasome Endopeptidase ComplexProtein BindingProteolysisPurinesPyridinesSmall Molecule LibrariesUbiquitinationCCNK protein, humanCDK12 protein, humanCR8 compoundCyclin-Dependent KinasesCyclinsDDB1 protein, humanDNA-Binding ProteinsProteasome Endopeptidase ComplexPurinesPyridinesSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.